Abivax Share: Nearly 22% Lost in One Month, Then 2.5% Gained in Oversold Conditions
The Parisian biotech company specializing in inflammatory diseases is recovering ground mid-morning, following several weeks of selling pressure. The movement occurs in a rising Paris market, while the share remains far from its moving averages and short selling has declined.
A Rebound of 2.27% That Leaves the Share Far from Its Moving Averages
The Abivax share gains 2.27% to €78.85 in trading, compared to €77.10 at the previous close, a level that also corresponds to its support. The rebound remains modest in light of the decline of recent weeks: The share loses 6.3% over seven days and 21.93% over one month. It stands 9.12% below its MA20 (€86.76) and 22.15% below its MA200 (€101.28), a sign of a still bearish trend in the medium term.
The RSI at 28 reflects an oversold configuration, which accompanies this first recovery movement. At the same time, the CAC 40 advances 0.94% and the SBF 120 0.98%, so the share is rising at a faster pace than the index, without, however, being among the strongest gainers of the session.
Short Positions Decline to 5.17% of Capital in One Month
Net short positions on Abivax are reported by five funds, for 5.17% of capital according to the declarations consulted, the latest of which dates from October 6. They were at 7.18% thirty days ago: the decline of 2.01 percentage points shows that short sellers unwound part of their bearish bets during the share's fall. A level that remains above 5% of capital underscores that institutional investors remain positioned against the value.
This figure reveals little about their intentions, and it is read primarily through its trend over several weeks. Abivax is listed in Paris and, in the form of ADS, on the Nasdaq, where volumes are higher. On the calendar front, the company presented its half-yearly results on September 21. It maintains financial visibility through the fourth quarter of 2029.
